Table 2.
Efficacy outcomes at week 12
| End point, n/N (%) | Hispanic subgroup | Non-Hispanic subgroup | ||||
|---|---|---|---|---|---|---|
| Secukinumab 300 mg | Secukinumab 150 mg | Etanercept | Secukinumab 300 mg | Secukinumab 150 mg | Etanercept | |
| PASI 75 | 80/86 (92.6)* | 80/97 (82.8) | 35/50 (69.2) | 495/600 (82.4)† | 426/592 (71.9)† | 120/273 (43.8) |
| PASI 90 | 61/86 (70.6)† | 58/97 (59.5)* | 16/50 (31.2) | 348/600 (58.0)† | 244/592 (41.2)† | 58/273 (21.2) |
| PASI 100 | 31/86 (35.9)‡ | 24/97 (25.1) | 5/50 (9.8) | 168/600 (28.1)† | 79/592 (13.4)¶ | 14/273 (5.0) |
| IGA mod 2011 0/1 | 65/86 (75.6)¶ | 64/97 (65.9)* | 22/50 (44.8) | 409/600 (68.2)† | 318/593 (53.5)† | 74/273 (27.0) |
Significance was determined by the Cochran–Mantel–Haenszel test. Missing values were handled by multiple imputation
IGA mod 2011 0/1 Investigator’s Global Assessment, 2011 modified version, improvement to scores of 0 or 1 (clear or almost clear skin), PASI 75/90/100 Psoriasis Area and Severity Index 75%/90%/100% improvement from baseline
* P < 0.05 for the comparison with etanercept
† P ≤ 0.0001 for the comparison with etanercept
‡ P < 0.01 for the comparison with etanercept
¶ P < 0.001 for the comparison with etanercept